MedTrace Logo

Ketamine Assisted Psychotherapy for Opioid Use Disorder

NCT04892251 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2023-07-05

No results posted yet for this study

Summary

This pilot clinical trial aims to assess the preliminary efficacy of ketamine as an adjunct for a mindfulness-based intervention for opioid use disorder.

Conditions

  • Opioid-use Disorder

Interventions

COMBINATION_PRODUCT

MORE+KAP

Mindfulness-Oriented Recovery Enhancement plus two sessions where 0.5 to 1.5 mg/kg of ketamine are administered intramuscularly

BEHAVIORAL

MORE

Mindfulness-Oriented Recovery Enhancement

Sponsors & Collaborators

Principal Investigators

  • Eric L Garland · University of Utah

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-05-20
Primary Completion
2023-12-30
Completion
2024-05-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04892251 on ClinicalTrials.gov